Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx (NASDAQ: RARE) granted 13,144 restricted stock units to nine newly hired non-executive officers under the Ultragenyx Employment Inducement Plan.

Rhea-AI Summary

Ultragenyx (NASDAQ: RARE) granted 13,144 restricted stock units to nine newly hired non-executive officers under the Ultragenyx Employment Inducement Plan.

The awards were approved by the compensation committee with a grant date of December 17, 2025 and reported December 19, 2025, as an inducement under Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years with 25% vesting each anniversary, subject to continuous employment on each vesting date.

Argus Dec 22 session

+3.73% close to close Open Argus

Details

News Market Reaction – RARE

On Dec 22, the first trading day after this news, RARE closed 3.73% above the previous close.

Data tracked by StockTitan Argus for the Dec 22 session.

Market Context

This announcement details a routine employment inducement grant of 13,144 restricted stock units to ...

Analysis

This announcement details a routine employment inducement grant of 13,144 restricted stock units to nine newly hired non‑executive officers, vesting over four years. It follows a period of significant updates, including Q3 revenue of $159.9M, a $400M Crysvita royalty transaction, and progress in the GTX‑102 program. Investors monitoring RARE may focus on how ongoing equity grants interact with the existing share base, upcoming late‑stage clinical readouts, and the company’s reiterated path toward GAAP profitability in 2027.

Key Figures

RSU grant size: 13,144 restricted stock units Number of recipients: 9 employees Vesting period: 4 years +1 more

RSU grant size

13,144 restricted stock units

Granted to nine newly hired non-executive officers on December 17, 2025

Number of recipients

9 employees

Newly hired non-executive officers receiving inducement RSUs

Vesting period

4 years

RSUs vest with 25% on each anniversary of the grant date

Annual vesting rate

25% per year

Portion of RSUs vesting on each grant date anniversary

Historical Context

5 past events · Latest: Nov 24

5 events

1. Nov 24

   Investor conferences

   24h Move

   +2.3%

   Participation in two early December 2025 healthcare investor conferences.

2. Nov 21

   Inducement grant

   24h Move

   -2.4%

   Grant of 18,180 RSUs to 12 new non‑executive officers under inducement plan.

3. Nov 04

   Q3 2025 earnings

   24h Move

   -3.0%

   Q3 revenue growth to $159.9M, reaffirmed 2025 guidance, path to 2027 GAAP profitability.

4. Nov 04

   Royalty sale deal

   24h Move

   -3.0%

   Sale of additional 25% Crysvita royalty interest to OMERS for $400M cash.

5. Oct 30

   Clinical trial update

   24h Move

   +1.7%

   First patient dosed in Aurora GTX‑102 study and Aspire Phase 3 fully enrolled.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, Nasdaq Listing Rule 5635(c)(4)

2 terms

restricted stock units financial

"reported the grant of 13,144 restricted stock units of the company’s common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NOVATO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 13,144 restricted stock units of the company’s common stock to nine newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of December 17, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ultragenyx (RARE) announce on December 19, 2025 about employee awards?

Ultragenyx announced a grant of 13,144 restricted stock units to nine newly hired non-executive officers.

When was the Ultragenyx inducement grant (RARE) dated and approved?

The awards had a grant date of December 17, 2025 and were approved by the compensation committee.

How do the Ultragenyx RSUs (RARE) vest for the new hires?

The RSUs vest over four years with 25% of shares vesting each anniversary, conditioned on continuous employment.

Under which plan and Nasdaq rule were Ultragenyx's (RARE) inducement awards granted?

They were granted under the Ultragenyx Employment Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received RSUs in Ultragenyx's December 2025 inducement grant (RARE)?

Nine newly hired non-executive officers received the 13,144 restricted stock units.

Does the December 2025 RSU grant for Ultragenyx (RARE) change outstanding share count immediately?

The announcement reports an award of RSUs; it does not state any immediate issuance or change to outstanding shares.